Benzinga | Nov 10, 2021 08:24AM EST

Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $75

Chardan Capital analyst Keay Nakae maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $92 to $75.